Biotechnology

Filter

Current filters:

None

Popular Filters

27 to 51 of 2433 results

Ardelyx appoints Jeremy Caldwell as executive vice president and chief scientific officer

Ardelyx appoints Jeremy Caldwell as executive vice president and chief scientific officer

11-12-2014

Biopharma commpany Ardelyx has appointed Jeremy Caldwell as executive vice president and chief scientific…

ArdelyxBiotechnologyBoardroomJeremy CaldwellUSA

Celgene appoints Wim Souverijns as vice president general manager for UK and Ireland

Celgene appoints Wim Souverijns as vice president general manager for UK and Ireland

11-12-2014

US biotech company Celgene has appointed Wim Souverijns as vice president general manager for the UK…

BiotechnologyBoardroomCelgene Corp.UKUK & Ireland

AusBiotech reflects on a year of advocacy and achievement

AusBiotech reflects on a year of advocacy and achievement

11-12-2014

For the Australian biotechnology industry and for trade group AusBiotech, the past year has been another…

AustraliaBiotechnologyFinancialPoliticsResearch

Navidea forms Macrophage Therapeutics unit to explore applications of Manocept

11-12-2014

US biotech firm Navidea Biopharmaceuticals has established a new business unit, Macrophage Therapeutics,…

BiotechnologyLymphoseekMacrophage TherapeuticsManagementManoceptNavidea BiopharmaceuticalsUSA

Biopharma market could be worth $41 billion this year, says Kalorama report

Biopharma market could be worth $41 billion this year, says Kalorama report

10-12-2014

Biopharma and vaccine production could be worth up to $41 billion this year, according to a report by…

BiologicBiotechnologyKaloramaKalorama InformationMarkets & Marketing

US Class Action law suit challenges pricing of Gilead's hepatitis-C drug Sovaldi

US Class Action law suit challenges pricing of Gilead's hepatitis-C drug Sovaldi

10-12-2014

US law firm Chimicles & Tikellis of Haverford, PA, has filed a law suit on behalf of the Southeastern…

Anti-viralsBiotechnologyGilead SciencesLawLegalPricingSocial IssuesSovaldiUnited StatesUSA

Spark Thera in potential $280 million hemophilia B deal with Pfizer

Spark Thera in potential $280 million hemophilia B deal with Pfizer

10-12-2014

US gene therapy start up Spark Therapeutics has entered into a global collaboration with pharma giant…

BiotechnologyHematologyLicensingPfizerSpark TherapeuticsSPK-RPE65USA

Positive top-line Ph III results with Lilly and Incyte’s baricitinib

Positive top-line Ph III results with Lilly and Incyte’s baricitinib

09-12-2014

US pharma major Eli Lilly and partner Incyte Corp today revealed that the Phase III RA-BEACON study of…

Anti-Arthritics/RheumaticsbaricitinibBiotechnologyEli LillyIncyteResearchUSA

Calithera gains exclusive, global license to Mars Symbioscience's arginase inhibitors

09-12-2014

Calithera Biosciences has signed an exclusive global license agreement with Mars Symbioscience, a division…

BiotechnologyCalithera BiosciencesGlobalLicensingMars SymbioscienceOncology

NICE now proposes to recommend Stelara for psoriatic arthritis

NICE now proposes to recommend Stelara for psoriatic arthritis

09-12-2014

UK health cost watchdog, the National Institute for Health and Care Excellence (NICE) has opened a consultation…

Anti-Arthritics/RheumaticsBiotechnologyInflammatory diseasesJanssenJohnson & JohnsonPricingRegulationStelaraUK

Official: Merck & Co to acquire Cubist for $8.4 billion

Official: Merck & Co to acquire Cubist for $8.4 billion

08-12-2014

Confirming weekend speculation and rumors, US pharma giant Merck & Co this morning said it has entered…

Antibiotics and Infectious diseasesBiotechnologyCubicinCubist PharmaceuticalsMerck & CoMergers & AcquisitionsZerbaxa

FDA approves new indication for Amgen's Xgeva

FDA approves new indication for Amgen's Xgeva

08-12-2014

USA-based Amgen says the US Food and Drug Administration has approved a new indication for Xgeva (denosumab),…

AmgenBiotechnologyOncologyRare diseasesRegulationUSAXgeva

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

Sandoz demonstrates safety and efficacy of Neupogen biosimilar

08-12-2014

Sandoz, the generics subsidiary of Swiss pharma major Novartis, has today released Phase III data that…

AmgenBiosimilarsBiotechnologyFilgrastimNeupogenNovartisOncologyResearchSandoz

ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial

ASH 2014: Amgen and Onyx report primary endpoint met in Kyprolis combination trial

08-12-2014

USA-based Amgen and its subsidiary Onyx Pharmaceuticals announced the results of the Phase III ASPIRE…

AmgenBiotechnologyDexamethasoneKyprolisOncologyOnyx PharmaceuticalsResearchRevlimid

Credit Suisse sees PTC Therapeutics as a top stock pick

05-12-2014

Credit Suisse has released a biotech research report from analysts Jason Kantor and Jeremiah Shepard…

BiotechnologyFinancialNeurologicalPTC TherapeuticsRare diseasesRegulationTranslarna

AusBiotech argues for boosting commercial returns from research

05-12-2014

Trade group AusBiotech has made a submission to the Australian federal government’s consultation regarding…

AustraliaBiotechnologyFinancialPoliticsResearch

US FDA approves new indication for Incyte’s Jakafi

US FDA approves new indication for Incyte’s Jakafi

05-12-2014

The US Food and Drug Administration yesterday approved a new use for Incyte Corp’s Jakafi (ruxolitinib)…

BiotechnologyIncyteJakafiOncologyRegulationUSA

Government action needed to slash prices for hepatitis C treatments, says US advocacy

Government action needed to slash prices for hepatitis C treatments, says US advocacy

04-12-2014

The US federal government should act to dramatically lower the cost of new and prohibitively pricey medications…

Anti-viralsBiotechnologyGilead SciencesPricingSovaldiUSA

Array BioPharma to regain global rights to binimetinib from Novartis

04-12-2014

Shares of US biotech firm Array BioPharma leapt 22.8% to $4.80 in after-hours trading on Wednesday, after…

Array BioPharmabinimetinibBiotechnologyGlobalLicensingNovartisOncology

27 to 51 of 2433 results

Back to top